Literature DB >> 7594644

In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo.

A Gilhar1, B Zelickson, Y Ulman, A Etzioni.   

Abstract

There are conflicting results regarding the role of autoantibodies in the pathogenesis of vitiligo. To examine their in vivo effect, human skin was transplanted onto nude mice injected with purified IgG obtained from patients with vitiligo and from controls. The effect was evaluated by several techniques. Dihydroxyphenylalanine staining revealed a marked decrease in the number of melanocytes in skin grafted onto mice injected with patients' IgG. Direct immunofluorescence staining demonstrated the presence of human IgG throughout the epidermis in specimens injected with purified IgG from vitiligo patients. No staining was observed when control IgG was injected. Electron microscopy studies demonstrated a marked decrease in melanin pigmentation with only rare melanosomes and melanocytes detected in grafts injected with patients' IgG. Thus all three techniques showed the destructive effect of vitiligo patients' serum on melanocytes. Our study highlights the important role of autoantibodies in the pathogenesis of vitiligo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594644     DOI: 10.1111/1523-1747.ep12324456

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  15 in total

1.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

2.  Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo.

Authors:  S Sanchez-Sosa; M Aguirre-Lombardo; G Jimenez-Brito; A Ruiz-Argüelles
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

Review 3.  Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo.

Authors:  John E Harris
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

Review 4.  Therapeutic implications of autoimmune vitiligo T cells.

Authors:  Kepa Oyarbide-Valencia; Jasper G van den Boorn; Cecele J Denman; Mingli Li; Jeremy M Carlson; Claudia Hernandez; Michael I Nishimura; Pranab K Das; Rosalie M Luiten; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2006-05-06       Impact factor: 9.754

5.  Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study.

Authors:  A Ruiz-Argüelles; M García-Carrasco; G Jimenez-Brito; S Sánchez-Sosa; B Pérez-Romano; J Garcés-Eisele; C Camacho-Alarcón; V Reyes-Núñez; M Sandoval-Cruz; C Mendoza-Pinto; A López-Colombo
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

6.  Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.

Authors:  E A Waterman; E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 7.  Stability in Vitiligo: Is there a Perfect Way to Predict it?

Authors:  Kanika Sahni; Davinder Parsad
Journal:  J Cutan Aesthet Surg       Date:  2013-04

8.  Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review.

Authors:  V Arya; M Bansal; L Girard; S Arya; A Valluri
Journal:  Case Rep Dermatol       Date:  2010-08-27

9.  IFN-γ, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens.

Authors:  Fengying Shi; Gisela F Erf
Journal:  J Invest Dermatol       Date:  2011-11-24       Impact factor: 8.551

10.  Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.

Authors:  Randal K Gregg; Lisa Nichols; Yiming Chen; Bao Lu; Victor H Engelhard
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.